Federal Health Grants

This funding opportunity supports researchers investigating the role of T-cells in the central nervous system related to HIV, aiming to understand their impact on viral reservoirs and neurological complications, with a focus on innovative therapeutic strategies.

This funding opportunity supports organizations in developing and providing specialized immunologic reagents for nonhuman primate research, enhancing studies on immune-mediated and infectious diseases.

This funding opportunity supports innovative research projects in computational genomics and data science, encouraging the development of tools and methods that enhance genomic research and its applications across various diseases to improve human health.

This funding opportunity supports a national initiative to educate and empower Medicare beneficiaries and their families against fraud and abuse, by providing resources and training to organizations dedicated to this mission across the U.S. and its territories.

The FY24 LCRP Translational Research Award mechanism supports advanced translational research that will foster transformation of promising ideas in lung cancer into clinical applications. Translational research may be defined as an integration of basic science and clinical observations. Observations that drive a research idea may originate from a laboratory discovery, population-based studies, or a clinicians firsthand knowledge of patient care. The ultimate goal of translational research is to move a concept or observation forward into clinical application. However, Principal Investigators (PIs) should not view translational research as a one-way continuum from bench to bedside but can include a reciprocal flow of ideas and information between basic science and clinical science (bench to bedside and/or bedside to bench). Research applications only in the area of mesothelioma will not be accepted. This mechanism is intended to fund a broad range of translational studies with two different funding levels. The following are general examples, although not all-inclusive, of the type of research projects that would be appropriate to propose under the current program announcement:Funding Level 1: Advanced preclinical studies aimed at translating results from animal studies to applications with human samples/cohorts (The Translational Research Award is not intended to support initial mechanistic studies of a new target.) Late-stage preclinical work leading to/preparing for a clinical trial, e.g., Investigational New Drug (IND) application submission Correlative studies that are associated with an open/ongoing or completed clinical trial, e.g., projects that utilize biospecimens from clinical trials to improve clinical management of lung cancer and/or define new areas of research Projects that develop endpoints for clinical trialsFunding Level 2 Pilot clinical trials where limited clinical testing (e.g., small sample size) of a novel intervention is necessary to inform the next step in the continuum of translational researchPreliminary lung cancer relevant data to support the feasibility of the research hypotheses and research approaches are required.

This funding opportunity supports innovative research to develop or improve technologies that enhance fertility outcomes, particularly in assisted reproductive technologies, and is open to a wide range of organizations, including educational institutions, nonprofits, and for-profit entities.

This funding opportunity supports promising predoctoral students in health-related fields to receive personalized research training and mentorship, helping them develop into independent research scientists.

The NIH INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project seeks to improve health and quality-of-life for individuals with Down syndrome. This FOA is intended to support meritorious small research projects focused on analyses of genomics other -omics, clinical and phenotypic datasets related to Down syndrome research, with an emphasis on elucidating the underlying etiologies of risk and resiliencies to co-occurring health conditions. Development of approaches, tools, or algorithms appropriate for analyzing data relevant to Down syndrome and facilitating data sharing within the research community through the INCLUDE Data Hub may also be proposed.

The purpose of this Notice of Funding Opportunity (NOFO) is to support research that includes education, outreach, and clinical access to improve the screening, diagnosis, and treatment of cancers among American Indians and Alaska Natives, particularly those living in rural communities.

This funding opportunity supports researchers conducting early phase clinical trials on natural products, such as botanicals and dietary supplements, to evaluate their effects and potential benefits for human health.

This funding opportunity provides financial support to nonprofit and public organizations to deliver comprehensive primary health care services to underserved communities across the United States and its territories.

This funding opportunity provides financial support to organizations serving Native Hawaiians to enhance their capacity in preventing and responding to domestic violence and family violence through culturally relevant resources and training.

The NIH Directors New Innovator Award Program supports early stage investigators of exceptional creativity who propose bold and highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the research workforce. To support innovative and novel research across the vast NIH mission, individuals from diverse backgrounds (including those from underrepresented groups; see Notice of NIHs Interest in Diversity) and from the full spectrum of eligible institutions in all geographic locations are encouraged to apply to this Notice of Funding Opportunity. Applications in all topics relevant to the broad mission of NIH are welcome, including, but not limited to, behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research. The NIH Director's New Innovator Award Program complements other ongoing efforts by NIH and its Institutes and Centers to fund early stage investigators. The NIH Directors New Innovator Award Program is a component of the High-Risk, High-Reward Research (HRHR) Program of the NIH Common Fund.

This funding opportunity supports researchers conducting experimental studies with humans to explore how sleep and circadian rhythms are connected to substance use disorders, aiming to improve understanding and treatment of these issues.

This funding opportunity supports researchers in developing innovative technologies that can improve the speed and efficiency of creating new therapies for patients.

This funding opportunity supports programs that engage underserved communities, enhance behavioral health services, promote environmental stewardship, and provide significant benefits to AmeriCorps members, particularly focusing on youth, veterans, and public health initiatives.

This grant provides funding for research centers focused on improving the safety and health of workers in agriculture, forestry, and fishing through evidence-based solutions and community outreach.

This grant provides resources and support to clinical sites across the U.S. to enhance their ability to diagnose rare and undiagnosed diseases, ultimately improving patient care and fostering scientific discovery.

This funding opportunity supports innovative research to improve communication and relationships between patients and clinicians, aiming to enhance health outcomes for underserved populations facing health disparities.

This Notice of Funding Opportunity (NOFO) invites applications for the continued support and advancement of the Mutant Mouse Resource and Research Centers (MMRRC). The MMRRC consortium is expected to facilitate research by identifying, acquiring, evaluating, characterizing, cryopreserving, and distributing mutant mouse strains to qualified biomedical investigators. A regional network of four MMRRCs and an Informatics, Coordination and Service Center (ICSC) collectively serve the needs of the biomedical research community for transgenic, knockout and other genetically-engineered mutant mice and related biomaterials. MMRRC strains are held to the highest standards to optimize reproducibility of studies and assure scientific rigor and transparency; all submitted strains are thoroughly reviewed and documented and include additional quality control measures. The Program Director/Principal Investigator (PD/PI) of each MMRRC in addition to the major resource activities is required to develop a small high risk, high return, research pilot project that complements the goals and needs of the MMRRC consortium. ORIP intends to fund up to four awards, but the overall number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications Award Budget Requested Direct Costs must reflect actual needs of the project. For Renewal (a.k.a. Type 2) applications, no more than a 5 percent (direct cost) increase from the last non-competing year will be accepted. ORIP intends to fund up to four awards, but the overall number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications